PPARγ agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
B Zinman - Diabetes, obesity & metabolism, 2001 - search.ebscohost.com
B Zinman
Diabetes, obesity & metabolism, 2001•search.ebscohost.comPPARg agonists in type 2 diabetes: how far have we come in Page 1 PPARg agonists in type 2
diabetes: how far have we come in `preventing the inevitable'? A review of the metabolic effects
of rosiglitazone Bernard Zinman Division of Endocrinology and Metabolism, Department of
Medicine, University of Toronto and Samuel Lunenfeld Research Institute of Mount Sinai
Hospital, Toronto, Ontario, Canada Keywords: rosiglitazone, hyperglycaemia, insulin resistance,
b-cell function, cardiovascular risk Introduction Progressive deterioration of glycaemic control …
diabetes: how far have we come in `preventing the inevitable'? A review of the metabolic effects
of rosiglitazone Bernard Zinman Division of Endocrinology and Metabolism, Department of
Medicine, University of Toronto and Samuel Lunenfeld Research Institute of Mount Sinai
Hospital, Toronto, Ontario, Canada Keywords: rosiglitazone, hyperglycaemia, insulin resistance,
b-cell function, cardiovascular risk Introduction Progressive deterioration of glycaemic control …
Abstract
Examines the metabolic effects of rosiglitazone, a proliferator-activated receptor-gamma agonist used in the treatment of type 2 diabetes. Glycemic control; Insulin sensitivity and Beta-cell function; Abdominal obesity; Hypertension; Dyslipidemia.
search.ebscohost.com